2001
DOI: 10.1023/a:1012554328801
|View full text |Cite
|
Sign up to set email alerts
|

Untitled

Abstract: Treatment options and prognosis remains poor for patients with recurrent glioblastoma multiforme. These tumors are highly vascularised and over express angiogenic factors such as vascular endothelial growth factor and may potentially be responsive to antiangiogenic therapies. We present the results of a phase II trial of Thalidomide, an antiangiogenic agent, in the treatment of recurrent glioblastoma multiforme. Patients were treated with 100 mg/day of Thalidomide, increased at weekly intervals by 100 mg to a … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
18
0

Year Published

2004
2004
2014
2014

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 113 publications
(18 citation statements)
references
References 21 publications
0
18
0
Order By: Relevance
“…Thalidomide has also been evaluated for its anti-angiogenic properties. As a single agent, thalidomide was found to have a median survival of 31 weeks and 6 month PFS of 18% in patients with recurrent glioblastoma (Marx et al 2001). In patients with recurrent high grade gliomas, the median TTP was 10 weeks with a median overall survival of 28 weeks (Fine et al 2000).…”
Section: Discussionmentioning
confidence: 99%
“…Thalidomide has also been evaluated for its anti-angiogenic properties. As a single agent, thalidomide was found to have a median survival of 31 weeks and 6 month PFS of 18% in patients with recurrent glioblastoma (Marx et al 2001). In patients with recurrent high grade gliomas, the median TTP was 10 weeks with a median overall survival of 28 weeks (Fine et al 2000).…”
Section: Discussionmentioning
confidence: 99%
“…4. Chromatogram showing resolution of R- [2] and S-thalidomide [3] (but with incomplete resolution of phenacetin, internal standard) [1], when using a mobile phase of 30% acetonitrile in ammonium formate (20 mM, pH 5.4). internal standard may be required.…”
Section: Discussionmentioning
confidence: 99%
“…Thalidomide undergoes hydrolytic degradation at higher pH, whereas a lower pH tends to produce a poorer baseline, noticeably around the times of the phenacetin and R-thalidomide peaks, due to interference from citrate carried over from the buffer. [1], R-thalidomide [2] and S-thalidomide [3] from rat serum (0.2 ml) spiked at the lower limit of the quantitation; (C) spiked rat serum (0.2 ml) containing 5.0 g/ml thalidomide (0.6 ml serum extracted); (D) a sample of rat serum (0.2 ml) found to be containing 5.1 g/ml R-thalidomide and 2.5 g/ml S-thalidomide.…”
Section: Chromatographymentioning
confidence: 99%
See 1 more Smart Citation
“…In the field of palliative care, reports on the use of TH date back to the 1960s [17,18,19,20]. Several reports on the use of TH with palliative and anti-angiogenic intention for patients with malignant gliomas have been published, which are summarized in table 1[21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42]. Most of them, including the most recent studies, failed to meet the expectations of the investigators regarding the efficacy of an alternative anti-angiogenic agent.…”
Section: Introductionmentioning
confidence: 99%